Page 2,850«..1020..2,8492,8502,8512,852..2,8602,870..»

My story so far with Ulcerative Colitis – Video

Posted: Published on January 8th, 2015

My story so far with Ulcerative Colitis In this video I explain my story in more depth. Sorry I keep scratching my face - I will go in to why I think I'm doing this in the next video!! By: kateellenberry … Continue reading →

Posted in Ulcerative Colitis | Comments Off on My story so far with Ulcerative Colitis – Video

Treatment of Inpatients with Severe, Refractory Ulcerative Colitis – Video

Posted: Published on January 8th, 2015

Treatment of Inpatients with Severe, Refractory Ulcerative Colitis Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Treatment of Inpatients with Severe, Refractory Ulcerative Colitis – Video

Should We Change How We Position Biologics for Use in Ulcerative Colitis? – Video

Posted: Published on January 8th, 2015

Should We Change How We Position Biologics for Use in Ulcerative Colitis? Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Should We Change How We Position Biologics for Use in Ulcerative Colitis? – Video

Can You Solve the Case: Unknowns from Colonoscopies of Ulcerative Colitis Patients – Video

Posted: Published on January 8th, 2015

Can You Solve the Case: Unknowns from Colonoscopies of Ulcerative Colitis Patients Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healt... By: ImedexCME … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Can You Solve the Case: Unknowns from Colonoscopies of Ulcerative Colitis Patients – Video

Galapagos Initiates Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients

Posted: Published on January 8th, 2015

By RTT News, January 08, 2015, 01:43:00 AM EDT (RTTNews.com) - Galapagos NV (GLPGF.PK, GLPYY.PK), a Belgium-based clinical stage biotech company, announced Thursday that it has initiated a Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205, a potential novel treatment for Inflammatory Bowel Diseases. GLPG1205 arises from Galapagos' target discovery platform and is fully proprietary to the company. The firm noted that GLPG1205 ('1205) inhibits GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases or IBD. Galapagos has shown that GPR84 plays a key role in IBD and that '1205 is a selective inhibitor of GPR84 and very effective in pre-clinical models for IBD. In Phase 1 studies, '1205 showed good safety, full blockage of GPR84, and favorable drug-like properties. The first patients in this double-blind, placebo controlled study will initiate their treatment this week. Galapagos said the clinical Proof-of-Concept Phase 2 trial for '1205 will involve approximately 60 patients with moderate to severe ulcerative colitis. The aim is to evaluate the efficacy, safety and tolerability and pharmacokinetics of '1205, and to explore the effects of '1205 on selected biomarkers in this patient population. Galapagos has received full approvals to start the trial … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Galapagos Initiates Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients

Arena soars on results of autoimmune drug

Posted: Published on January 8th, 2015

Arena Pharmaceuticals is headquartered in San Diego. / photo by Eduardo Contreras * U-T Arena Pharmaceuticals of San Diego has successfully completed an early phase clinical trial of a potential autoimmune drug, the biotech company said Wednesday. It plans to launch further studies of the medication for the purpose of treating ulcerative colitis and Crohns disease. Arenas shares surged after the announcement, closing at $5.85, up 76 percent for the day. The companys market value rose past the billion-dollar mark to $1.3 billion, a level it hadnt reached since late June. The drug, APD334, was found in the Phase 1b clinical trial to lower the level of white blood cells called lymphocytes by up to 69 percent. The lymphocyte counts returned to their previous levels about a week after the drug was given. Lymphocyte reduction has been linked to the effectiveness of autoimmune drugs targeting multiple sclerosis, ulcerative colitis and Crohns disease, said Craig Audet, Arenas senior vice president of operations and head of global regulatory affairs. The drugs on the market now that treat these conditions have lymphocytes lowering somewhere in the range of 60 to 70 percent, and they show clinical efficacy, Audet said. Were right in the … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Arena soars on results of autoimmune drug

Sammys at it again: Hilo native taking on Kauai to raise awareness of muscular dystrophy, bullying

Posted: Published on January 8th, 2015

Hilo native Daryl Sammy Sampaga is at it again. A year after making headlines in early 2014 for trekking the Big Island-round to raise awareness of muscular dystrophy and to support keiki with disabilities, Sampaga will take on the island of Kauai by two means: walking and paddling. Sampaga will begin the journey, nicknamed Operation Paddle and Walk for Dreams Kauai Island 2015, on Jan. 17. Before I started (the Big Island) walk, I had mentioned to everyone that I was going to hit this island and then hit all the other islands, Sampaga said. They doubted me the first time, saying you not going make em, and no one every tried and I said I will try, even if I got to crawl, I will crawl and I did. The Kauai project, the latest of his nonprofit, Operation Sammy Muscular Dystrophy, will take Sampaga, who has muscular dystrophy, which affects his leg muscles, on a more than 100-mile trip around the Garden Island. The journey will comprise 78 miles of walking and up to 32 miles of paddling along the Na Pali Coast, Sampaga told West Hawaii Today on Tuesday. He will begin the feat first by paddling the … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Sammys at it again: Hilo native taking on Kauai to raise awareness of muscular dystrophy, bullying

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related …

Posted: Published on January 8th, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034. SciFluors SF0034 is a potent and selective neuronal potassium channel activator, designed to be a significantly improved version of the first-in-class KCNQ2/3 activator drug, ezogabine (POTIGA). POTIGA was approved in 2011 for treatment of partial-onset epilepsy in adults, but its clinical use was severely restricted in 2013 due to latent toxicities which are not thought to be associated with its mechanism of action. Scott Edwards, Ph.D., Vice President and General Manager, said, The issuance of the patent covering SF0034 provides further validation of our fluorine-centered approach to rapidly discover new transformational therapies for patients with serious illnesses. SF0034 demonstrates how the appropriate fluorine-containing modifications can improve the potency and selectivity of a molecule to address efficacy and safety liabilities. Dr. Edwards is the lead on the SF0034 therapeutic program, which is targeted for development in partial-onset epilepsy and potentially for the recently identified orphan disease, a rare pediatric disorder known as KCNQ2 encephalopathy. The … Continue reading →

Comments Off on SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related …

Office Hours with Dr. Tim Buie: Acid Reflux & Autism – Video

Posted: Published on January 8th, 2015

Office Hours with Dr. Tim Buie: Acid Reflux Autism Autism Speaks is pleased to launch a new expert-advice video series Office Hours with acclaimed pediatric gastroenterologist Timothy Buie, of MassGeneral... By: Autism Speaks … Continue reading →

Comments Off on Office Hours with Dr. Tim Buie: Acid Reflux & Autism – Video

SJH earns stroke care designation

Posted: Published on January 8th, 2015

HSHS St. Josephs Hospital (Highland) has been officially awarded Emergent Stroke Ready Hospital (ESRH) designation by the Illinois Department of Public Health (IDPH). Receiving this designation by the State of Illinois is validation to the importance that St. Josephs Hospital (SJH) plays in delivering specialized emerging services to local residents, says Peggy Sebastian, President and CEO, SJH. (SJH) made the conscious decision to apply for this designation because we have the ideal mix of medical professionals, diagnostic capabilities, and treatment programs in place to provide emergency stroke care. SJH is just one (1) of the very few hospitals in the region that have a state-awarded stroke center designation. In January 2014, IDPH released the hospital stroke center designation criteria allowing hospitals to voluntarily pursue stroke center designation as an ESRH. Hospitals in Illinois seeking ESRH designation must meet specific criteria to be eligible for State designation aligning with nationally recognized, evidence-based standards, such as those from the American Heart/Stroke Association and Brain Attack Coalition. Illinois was one of the first states in the nation to incorporate another level of stroke center into its law. ESRHs - hospitals that diagnose, treat, and transport acute stroke patients to a higher level of … Continue reading →

Comments Off on SJH earns stroke care designation

Page 2,850«..1020..2,8492,8502,8512,852..2,8602,870..»